Top Markets
#1 Black Phoenix Black Phoenix +355.27%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +62.66%
#4 OpenEden OpenEden +56.84%
#5 Akedo Akedo +56.63%
#6 BasedHype BasedHype +27.37%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +20.66%
#9 Humanity Humanity +17.61%
#10 Ether.fi Ether.fi +17.54%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Rank in Stocks #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Share Price
$2.35
Last synced: 2022-09-07
Market Cap
$162.94K
Change (1 day)
2.17%
Change (1 year)
0.00%
Country
US
Trade Brickell Biotech, Inc. (BBI)

Category

Healthcare
Revenue for Brickell Biotech, Inc. (BBI)
Revenue in Aug 2026 TTM: 0
According to Brickell Biotech, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Brickell Biotech, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE